Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. President and CEO Chao Xingjuan reported an open-market sale of 2,084 shares of common stock on February 23, 2026 at $19.79 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.
After this transaction, she directly owned 725,164 common shares. The filing also notes an indirect holding of 369,088 shares through the ACP 2021 Trust, where she is a co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership beyond her pecuniary interest.
CeriBell, Inc. is a medical technology company focused on point-of-care EEG for critically ill patients, using AI-powered algorithms to detect seizures, delirium and other serious neurological conditions. Its Ceribell System combines disposable headbands or headcaps, a pocket-sized recorder and a cloud portal for real-time monitoring.
As of December 31, 2025, the system had been adopted by more than 600 U.S. hospitals, targeting a U.S. addressable market it estimates at over $3.5 billion when including seizures and delirium. In 2025 CeriBell generated $89.1 million in revenue, up from $65.4 million in 2024, with a gross margin of 88% and a net loss of $53.4 million.
Growth is supported by expanding clinical indications: FDA 510(k) clearance for its Clarity algorithm to diagnose electrographic status epilepticus in adults and for delirium monitoring, plus Breakthrough Device Designation for an in‑development large vessel occlusion stroke detection solution. The company relies on recurring revenue from single-use Wearables and subscriptions to its software and hardware platform.
Ceribell, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining loss-making. Fourth quarter revenue rose 34% to $24.8 million, with product revenue up 33% and subscription revenue up 37%. Gross margin was a high 87%, but operating expenses increased 24% to $36.2 million, leading to a net loss of $13.5 million, or $0.36 per share.
For full year 2025, revenue grew 36% to $89.1 million, driven by both product and subscription sales. Gross profit reached $78.3 million with an improved gross margin of 88%, but operating expenses rose 42% to $136.7 million, resulting in a net loss of $53.4 million, or $1.46 per share. Ceribell ended the year with $159.3 million in cash, cash equivalents, and marketable securities and 647 active accounts.
The company highlighted multiple regulatory milestones, including two FDA 510(k) clearances and an FDA Breakthrough Device Designation, and guided 2026 revenue to $111–115 million, implying about 25–29% growth over 2025.
CBLL: A Form 144 excerpt lists multiple reported sales of common stock by David J. Foehr. The excerpt shows sales on 12/03/2025 of 5,265 shares for $88,609.95; on 01/05/2026 of 5,556 shares for $125,565.60; on 02/03/2026 of 5,556 shares for $111,120.00; and on 02/23/2026 of 569 shares for $11,263.07. The excerpt also notes restricted stock vesting on 02/20/2026 for 781 shares identified as compensation.
Insider Form 144 reports multiple dispositions of common stock. The filing lists planned sale/transfer of 705 common shares associated with a 02/20/2026 restricted stock vesting through Fidelity Brokerage Services LLC. It also discloses three recent open-market dispositions by Raymond Woo of 11,112 shares each on 12/01/2025, 01/02/2026, and 02/02/2026 with aggregate proceeds shown per sale.
Xingjuan Chao reported intent to sell 2,084 common shares associated with restricted stock vesting on 02/20/2026. The filing also discloses prior dispositions of 79,000 shares on 01/05/2026 and 39,000 shares on 02/04/2026, with cash amounts shown for each trade.
Scott E. Blumberg reported a sale of common stock. He indicated an intent to sell 808 shares of Common Stock on 02/20/2026 tied to restricted stock vesting as issuer compensation. The filing also records a prior sale of 36,000 shares on 12/22/2025 for $756,000.
David J. Foehr reported sales of Common stock and a proposed resale notice under Rule 144. The filing lists three recent sales: 5,265 shares on 12/03/2025, 5,556 shares on 01/05/2026, and 5,556 shares on 02/03/2026. It also shows a restricted stock vesting event dated 02/20/2026 involving 569 shares and identifies Fidelity Brokerage Services LLC as the broker.
Ceribell, Inc. director Josef Parvizi, through the Josef Parvizi Trust, sold 16,714 shares of common stock in open-market transactions on February 19, 2026 under a Rule 10b5-1 trading plan adopted on August 18, 2025.
The weighted average sale price was $20.27 per share, with individual trades between $20.00 and $20.77. Following the sale, the Josef Parvizi Trust held 722,652 shares. Separate Innovation ACP Trust and ACP 2021 Trust holdings were 907,911 and 369,088 shares, respectively, where Parvizi is a co-trustee and may be deemed to share beneficial ownership but disclaims it except to the extent of his pecuniary interest.